United Therapeutics Slides Toward Steepest Decrease in Three Years After 4Q Earnings Miss

Dow Jones

Feb 27

By Sabela Ojea

Shares of United Therapeutics fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations.

The stock was down 10%, to $321.90, in Wednesday trading. Shares are down 8.8% year to date, and have fallen 42% over the past 12 months.

The biotechnology company posted a net profit of $301.3 million, or $6.19 a share, compared with $217.1 million, or $4.36 a share, for the same period a year earlier. Analysts surveyed by FactSet had expected earnings of $6.40 a share.

Revenue rose 20%, to $735.9 million, offset by a 2.1% decline in Adcirca sales. Wall Street had expected revenue of $734.7 million, according to FactSet.

Adcirca is used to treat pulmonary arterial hypertension.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

February 26, 2025 12:08 ET (17:08 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2514863270"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514863270\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514863270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 01:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514863270","market":"other","top_or_hot":-1,"title":"United Therapeutics Slides Toward Steepest Decrease in Three Years After 4Q Earnings Miss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations. \n</p>\n<p>\n  The stock was down 10%, to $321.90, in Wednesday trading. Shares are down 8.8% year to date, and have fallen 42% over the past 12 months. \n</p>\n<p>\n  The biotechnology company posted a net profit of $301.3 million, or $6.19 a share, compared with $217.1 million, or $4.36 a share, for the same period a year earlier. Analysts surveyed by FactSet had expected earnings of $6.40 a share. \n</p>\n<p>\n  Revenue rose 20%, to $735.9 million, offset by a 2.1% decline in Adcirca sales.  Wall Street had expected revenue of $734.7 million, according to FactSet. \n</p>\n<p>\n  Adcirca is used to treat pulmonary arterial hypertension. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2025 12:08 ET (17:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Therapeutics Slides Toward Steepest Decrease in Three Years After 4Q Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Therapeutics Slides Toward Steepest Decrease in Three Years After 4Q Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-27 01:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations. \n</p>\n<p>\n  The stock was down 10%, to $321.90, in Wednesday trading. Shares are down 8.8% year to date, and have fallen 42% over the past 12 months. \n</p>\n<p>\n  The biotechnology company posted a net profit of $301.3 million, or $6.19 a share, compared with $217.1 million, or $4.36 a share, for the same period a year earlier. Analysts surveyed by FactSet had expected earnings of $6.40 a share. \n</p>\n<p>\n  Revenue rose 20%, to $735.9 million, offset by a 2.1% decline in Adcirca sales.  Wall Street had expected revenue of $734.7 million, according to FactSet. \n</p>\n<p>\n  Adcirca is used to treat pulmonary arterial hypertension. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2025 12:08 ET (17:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514863270","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514863270","pubTimestamp":1740589680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of United Therapeutics fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations.The stock was down 10%, to $321.90, in Wednesday trading. Shares are down 8.8% year to date, and have fallen 42% over the past 12 months.The biotechnology company posted a net profit of $301.3 million, or $6.19 a share, compared with $217.1 million, or $4.36 a share, for the same period a year earlier. Analysts surveyed by FactSet had expected earnings of $6.40 a share.Revenue rose 20%, to $735.9 million, offset by a 2.1% decline in Adcirca sales.  Wall Street had expected revenue of $734.7 million, according to FactSet.Adcirca is used to treat pulmonary arterial hypertension.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗"},"translate_title":"United Therapeutics第四季度盈利未达预期，股价跌至三年来最大跌幅","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of United Therapeutics fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations. \n\n\n  The stock was down 10%, to $321.90, in Wednesday trading. Shares are down 8.8% year to date, and have fallen 42% over the past 12 months. \n\n\n  The biotechnology company posted a net profit of $301.3 million, or $6.19 a share, compared with $217.1 million, or $4.36 a share, for the same period a year earlier. Analysts surveyed by FactSet had expected earnings of $6.40 a share. \n\n\n  Revenue rose 20%, to $735.9 million, offset by a 2.1% decline in Adcirca sales.  Wall Street had expected revenue of $734.7 million, according to FactSet. \n\n\n  Adcirca is used to treat pulmonary arterial hypertension. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 12:08 ET (17:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}